- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Miraculins Inc. (TSXV:MOM) has signed a LOI with New Leaf Health to scout the DS(R) diabetes screen in the UK workplace wellness market. New Leaf is an industry leader specializing in the provision of effective employee wellness programs
Miraculins Inc. (TSXV:MOM) has signed a LOI with New Leaf Health to scout the DS(R) diabetes screen in the UK workplace wellness market. New Leaf is an industry leader specializing in the provision of effective employee wellness programs and health checks, helping businesses identify employee health risks and their associated costs, and then delivering customized interventions and solutions that support individual and organizational behaviour change.
As quoted in the press release:
Miraculins Inc. has executed a non-binding letter of intent (LOI) with New Leaf Health Ltd., one of the largest, most experienced workplace wellness providers in the United Kingdom, for the exclusive distribution of the Scout DS diabetes screen into the U.K. workplace wellness segment. New Leaf has a large and growing roster of clients including multi-nationals such as British Airways, Airbus and Volvo and it delivers evidence-based and cost-effective wellness programming throughout the entirety of the UK.
Under the LOI, the parties have acknowledged the general terms that will form part of a formalized agreement, including the award of exclusive distribution rights to New Leaf within the UK workplace wellness segment for a designated period of time with options for renewal, and New Leaf’s commitment to a minimum purchase of Scout DStrademark devices within the first year of screening operations. According to the terms of the LOI, Miraculins is also to receive an ongoing payment for every Scout DStrademark test conducted in the UK and additional revenue through the provision of branded test consumables.
President and CEO of Miraculins,Christopher Moreau, stated:
“Miraculins is pleased that the Scout DStrademark diabetes screen will soon be available to employees in both the private and public sector across the UK through New Leaf Health. The workplace is an ideal environment for the large-scale screening of employees for risk of diabetes, and our expansion into the UK marks the first distribution agreement among many we look forward to establishing, for the introduction of the Scout DStrademark into workplaces in countries throughout the European Union and around the world.”
Click here for the full Miraculins Inc. (TSXV:MOM) press release.
Click here for Miraculins Inc. (TSXV:MOM) profile
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.